# Endocannabinoid System & Cannabis-Induced Psychosis Research > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-risk-research/ > **Published:** 2026-03-03T21:43:50-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T12:01:13-04:00 > **Clinical Summary:** Explore cannabis-induced psychosis schizophrenia risk and clinical research on progression to schizophrenia and bipolar disorder. --- #### Clinical Takeaway A significant portion of individuals diagnosed with [cannabis-induced psychosis](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) will later develop a primary psychiatric disorder such as schizophrenia spectrum disorder or [bipolar disorder](https://cedclinic.com/cannabis-induced-appetite-satiety-bypass-thc-brain/). Clinicians should treat a cannabis-induced psychosis episode as a serious warning sign requiring close follow-up and long-term monitoring rather than a self-limiting event. Early identification and structured follow-up care may be critical in preventing or mitigating the progression to a chronic psychiatric condition. ### #24 Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis. **Citation:** Javed Mohammad Saad et al. *Prevalence of schizophrenia spectrum and [bipolar disorder](https://cedclinic.com/cannabis-induced-appetite-satiety-bypass-thc-brain/) among patients with cannabis induced psychosis: a [systematic review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) and meta-analysis.* BMC psychiatry. 2026. PMID: 41664079. **Study type:** Journal Article, Systematic Review, Meta-Analysis  |  **Topic area:** Psychosis  |  **CED Score:** 10 Design: 6 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: -2 Why This Matters This meta-analysis addresses a critical diagnostic challenge in clinical psychiatry by quantifying the risk that patients with cannabis-induced psychosis will subsequently develop schizophrenia spectrum or bipolar disorder, information essential for prognostic counseling and treatment planning. Understanding this progression rate helps clinicians distinguish transient cannabis-related psychotic episodes from prodromal presentations of primary psychiatric disorders, which carries substantial implications for long-term pharmacological management and patient outcomes. The findings establish an evidence-based foundation for developing standardized clinical guidelines in a treatment area currently lacking consensus protocols. **Quality Gate Alerts:** - Preclinical only **Abstract:** BACKGROUND: Distinguishing cannabis-induced psychosis from primary psychiatric disorders is difficult and has significant clinical and prognostic implications. Current treatment approaches lack standardized guidelines, potentially leading to the development of schizophrenia spectrum and bipolar disorder. This study systematically reviews the literature and provides a pooled prevalence of later developing these disorders following a cannabis-induced psychosis diagnosis. METHODS: We systematically reviewed Medline, Embase, Web of Science, Google Scholar, and PsychInfo for studies reporting on a group of patients with cannabis-induced psychosis and subsequent diagnoses of schizophrenia spectrum disorder, bipolar disorder, or both. The search was conducted until January 1, 2025. A modified version of the Newcastle-Ottawa scale was used to assess study quality. Random-effects meta-analyses were conducted to calculate pooled mean prevalence. Random-effects meta-regressions were used to identify predictors of higher prevalence. RESULTS: Our strategy identified 13 studies eligible for inclusion with a total population size of 7,515 which reported a total of 16 outcomes of interest. Among cannabis induced psychosis patients, 20% (95% CI:15.8-29.5%) later received a schizophrenia spectrum diagnosis, 5% (95% CI:2.7-6.9%) bipolar and 63% (95% CI:26.8-90.5%) unspecified (both). Compared to individuals receiving a later schizophrenia spectrum disorder diagnosis, patients were 76% less likely to develop bipolar disorder. Later diagnosis of an unspecified disorder showed an approximate 3 folds higher risk with an ARR of 2.52 (95% CI: 1.03-6.15) compared to schizophrenia spectrum disorder alone. CONCLUSIONS: Approximately one in five patients diagnosed with cannabis-induced psychosis will develop schizophrenia spectrum disorder, while one in twenty will be later diagnosed with bipolar disorder. Clinical Perspective This meta-analysis addresses a clinically important question: what proportion of patients presenting with cannabis-induced psychosis subsequently develop schizophrenia spectrum or bipolar disorder? While the pooled prevalence data will help quantify transition risk, clinicians should note several important confounders that likely influence these estimates, including variable diagnostic criteria across studies, heterogeneous follow-up periods, differences in cannabis potency and use patterns over time, and the inherent difficulty in distinguishing primary versus substance-induced psychosis at initial presentation. The quality and methodology of included studies will substantially affect the robustness of any meta-analytic conclusion, and publication bias toward positive transitions cannot be excluded. From a practical standpoint, these findings should inform risk stratification and counseling rather than deterministic predictions: a patient with cannabis-induced psychosis warrants careful longitudinal psychiatric follow-up and assessment for prodromal features or family history of psychotic or mood disorders, but [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) alone should not be assumed to inevitably trigger primary psychiatric illness in every individual [PubMed](https://pubmed.ncbi.nlm.nih.gov/41664079/)  |  [PMC Full Text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006112/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis-Induced Psychosis and Psychotic Disorders: Key Evidence](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-progression-insights/) Review key evidence linking cannabis-induced psychosis with psychotic disorders to inform clinical understanding and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). [Read More](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-progression-insights/) [Cannabis-Induced Psychosis & Schizophrenia Risk: Key Research](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-progression-insights/) Explore important research findings on the risk of schizophrenia following cannabis-induced psychosis episodes. [Explore Research](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-progression-insights/) [Cannabis-Induced Psychosis: Schizophrenia & Bipolar Risk](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-bipolar-progression/) Understand the prevalence and risk factors for schizophrenia and bipolar disorder after cannabis-induced psychosis diagnosis. [Learn More](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-bipolar-progression/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Endocannabinoid%20System%20%26%20Cannabis-Induced%20Psychosis%20Research&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-induced-psychosis-schizophrenia-risk-research%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-induced-psychosis-schizophrenia-risk-research%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Endocannabinoid%20System%20%26%20Cannabis-Induced%20Psychosis%20Research%20https%3A%2F%2Fcedclinic.com%2Fcannabis-induced-psychosis-schizophrenia-risk-research%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).